ing EML4-ALK fusion gene in non-small-cell lung cancer. Nature
8. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a
unique molecular class of lung cancer. J Clin Oncol 2012;30:863–70.
9. Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients
with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol
10. Kinno T, Tsuta K, Shiraishi K, et al. Clinicopathological features of
nonsmall cell lung carcinomas with BRAF mutations. Ann Oncol
11. Litvak AM, Paik PK, Woo KM, et al. Clinical characteristics and
course of 63 patients with BRAF mutant lung cancers. J Thorac
12. Villaruz LC, Socinski MA, Abberbock S, et al. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring
BRAF mutations in the Lung Cancer Mutation Consortium. Cancer
13. Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple
nonmelanoma cancers with BRAF V600 mutations. N Engl J Med
14. Planchard D, Kim TM, Mazieres J, et al. Dabrafenib in patients
with BRAF V600E-positive advanced non-small-cell lung cancer:
a single-arm, multicentre, open-label, phase 2 trial. Lancet Oncol
15. Gautschi O, Milia J, Cabarrou B, et al. Targeted therapy for patients
with BRAF-mutant lung cancer: results from the European EURAF
cohort. J Thorac Oncol 2015;10:1451–7.
16. Planchard D, Besse B, Groen HJ, et al. Dabrafenib plus trametinib
in patients with previously treated BRAF V600E-mutant metastatic
non-small cell lung cancer: an open-label, multicentre phase 2 trial.
Lancet Oncol 2016;17:984–93.
17. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine
kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer and
Association for Molecular Pathology. J Thorac Oncol 2013;8:823–59.
18. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing
guideline for selection of lung cancer patients for EGFR and ALK
tyrosine kinase inhibitors: guideline from the College of American
Pathologists, International Association for the Study of Lung Cancer
and Association for Molecular Pathology. Arch Pathol Lab Med
19. Leighl NB, Rekhtman N, Biermann WA, et al. Molecular testing for
selection of patients with lung cancer for epidermal growth factor
receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors:
American Society of Clinical Oncology endorsement of the College
of American Pathologists/International Association for the Study of
Lung Cancer/Association for Molecular Pathology guideline. J Clin
20. Paik PK, Varghese AM, Sima CS, et al. Response to erlotinib in
patients with EGFR mutant advanced non-small cell lung cancers
with a squamous or squamous-like component. Mol Cancer Ther
21. Paik PK, Drilon A, Fan PD, et al. Response to MET inhibitors in
patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov 2015;5:842–9.
22. Awad MM, Oxnard GR, Jackman DM, et al. MET Exon 14 mutations
in non-small-cell lung cancer are associated with advanced age, and
stage-dependent MET genomic amplification, and c-MET overexpression. J Clin Oncol 2016;34:721–30.
23. Schrock AB, Frampton GM, Suh J, et al. Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations.
J Thorac Oncol 2016;11:1493–502.
24. Reungwetwattana T, Liang Y, Zhu V, et al. The race to target MET
exon 14 skipping alterations in non-small cell lung cancer: The why,
the how, the who, the unknown, and the inevitable. Lung Cancer
25. Drilon A, Wang L, Hasanovic A, et al. Response to cabozantinib in
patients with RET fusion-positive lung adenocarcinomas. Cancer Discov
26. Lin JJ, Kennedy E, Sequist LV, et al. Clinical activity of alectinib in advanced RET-rearranged non-small cell lung cancer. J Thorac Oncol
27. Drilon A, Rekhtman N, Arcila M, et al. Cabozantinib in patients
with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol 2016;17:
28. Cappuzzo F, Bemis L, Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl
J Med 2006;354:2619–21.
29. Mazieres J. Barlesi F, Filleron T, et al. Lung cancer patients with
HER2 mutations treated with chemotherapy and HER2-targted
drugs: results from the European EUHER2 cohort. Annal Oncol
30. Ou SH, Schrock AB, Bocharov EV, et al. HER2 transmembrane
(TMD) mutations (V659/G660) that stabilize homo- and heterodi-merization are rare oncogenic drivers in lung adenocarcinoma that
respond to afatinib. J Thorac Oncol 2017;12:446–57.
31. Jordan EJ, Kim HR, Arcila ME, et al. Prospective comprehensive
molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emergent therapies. Cancer Discov
32. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of
oncogenic drivers in lung cancers to select targeted drugs. JAMA
33. Barlesi F, Mazieres J, Merlio JP, et al. Routine molecular profiling of
patients with advanced non-small-cell lung cancer: results of a 1-year
nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 2016;387:1415–26.
34. Rosell R, Moran T, Queralt C, et al. Screening for epidermal
growth factor receptor mutations in lung cancer. N Engl J Med
35. Rosell R, Karachaliou N, et al. Large-scale screening for somatic
mutations in lung cancer. Lancet 2016;387:1354–6.
36. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological
features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339–46.
37. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or
cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327–34.
38. Wu YL, Chou C, Liam CK, et al. First-line erlotinib versus gem-citabine/cisplatin in patients with advanced EGFR mutation-positive
non-small-cell lung cancer: analyses from the phase III, randomized,
open-label, ENSURE study. Ann Oncol 2015;26:1883–9.
39. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Eng J
Med 2010;362:2380– 8.
40. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus
docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an
open label, randomised phase 3 trial. Lancet Oncol 2010;11:121–8.
41. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy
as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a
multicentre, open-label, randomised, phase 3 study. Lancet Oncol